Company profile: Moderna
1.1 - Company Overview
Company description
- Provider of mRNA-based vaccines and therapeutics, including SPIKEVAX (FDA-approved COVID-19 vaccine), mRESVIA (RSV vaccine for older adults), and pipeline candidates mRNA-1283 (next-gen COVID, Phase 3), mRNA-1010 (flu, Phase 3), mRNA-1647 (CMV, Phase 3), and mRNA-4157 (individualized neoantigen cancer therapy, in collaboration with Merck).
Products and services
- MRESVIA®: A commercially available vaccine targeting respiratory syncytial virus for older adults, delivering protection against RSV infections and supplied through established commercial channels
- SPIKEVAX® (COVID-19 Vaccine, mRNA): An FDA-approved mRNA vaccine for 2024–2025 use that prevents COVID-19, delivering preventive immunization across approved use periods
- MRNA-1283: A Phase 3 next-generation COVID-19 vaccine engineered for storage at 2–5 ºC, delivering COVID-19 prevention with refrigerator-range cold-chain compatibility
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Moderna
Therakos
HQ: United States
Website
- Description: Provider of extracorporeal photopheresis immune modulation therapy to enhance immunologic response. Offers the THERAKOS CELLEX Photopheresis System used with UVADEX (methoxsalen) Sterile Solution to treat skin manifestations of CTCL, plus single-use procedural kits. Provides training via THERAKOS INSTITUTE, MyTHERAKOS portal documentation, and 24/7 customer, clinical, technical and product support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Therakos company profile →
NodThera
HQ: United Kingdom
Website
- Description: Provider of NLRP3 inflammasome inhibitor therapeutics targeting inflammatory and neuroinflammatory diseases, including brain-penetrant candidates. Lead asset NT-0796 is in Phase Ib/IIa for Parkinson’s disease and cardiovascular risk in obese patients; NT-0249 is optimized for low-dose chronic inflammatory therapy, with additional CNS and peripheral candidates under development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NodThera company profile →
Apitope
HQ: United Kingdom
Website
- Description: Provider of discovery and development of disease-modifying therapies for autoimmune and allergic diseases, including multiple sclerosis, Graves’ disease, Factor VIII intolerance and uveitis; first product candidate licensed to Merck Serono.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Apitope company profile →
NapaJen
HQ: United States
Website
- Description: Provider of oligonucleotide therapeutics and delivery technologies, offering NJA-730 for preventing acute immune diseases tied to bone marrow transplants; Napa9-SPG, a TLR9 agonist in preclinical immuno-oncology and vaccine adjuvant use; and a proprietary platform delivering nucleic acid drugs to immune cells. Provides partnerships for oligonucleotide development and NJA-730 licensing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NapaJen company profile →
Ception Therapeutics
HQ: United States
Website
- Description: Provider of payroll management services, delivering customizable payroll solutions and advanced software for seamless, timely processing; comprehensive administration covering tax filings and employee deductions; payroll compliance with the latest laws and regulations; and consulting on best practices and audit assistance, allowing businesses to focus on growth.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ception Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Moderna
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Moderna
2.2 - Growth funds investing in similar companies to Moderna
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Moderna
4.2 - Public trading comparable groups for Moderna
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →